Typical Uses:
Managing type 2 diabetes
Promoting weight loss in overweight or obese individuals
Improving cardiovascular health and reducing risk factors
 
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed to improve blood sugar control and promote weight loss in individuals with type 2 diabetes. By activating both GIP and GLP-1 receptors, Tirzepatide enhances insulin secretion, suppresses glucagon release, and slows gastric emptying. This dual action helps to regulate blood glucose levels and reduce appetite, leading to significant weight loss. Tirzepatide is also being studied for its potential benefits in improving cardiovascular health and reducing related risk factors. Studies have shown an average of 20% body weight loss over a 6-12 month period.
 
Benefits:
Blood Sugar Control: Improves insulin sensitivity and helps control blood sugar levels.
Weight Loss: Promotes weight loss through appetite suppression and improved metabolic function.
Cardiovascular Health: May reduce blood pressure and improve lipid profiles.
 
Possible Side Effects:
Gastrointestinal Issues: Nausea, vomiting, diarrhea, and constipation.
Injection Site Reactions: Pain, redness, or swelling at the injection site.
Decreased Appetite: Significant reduction in appetite, leading to potential weight loss.